Blood Test Could Reduce Antibiotic Use
News Nov 13, 2014
The information could help doctors decide when to prescribe antibiotics and possibly reduce overuse of the drugs, which can lead to antibiotic-resistant strains of bacteria.
Patients who go to hospital emergency departments (ED) with coughs and breathing difficulties could have pneumonia, bronchitis, asthma or chronic obstructive pulmonary disease, or even congestive heart failure, explained principal investigator David T. Huang, M.D., M.P.H., associate professor of critical care medicine and emergency medicine, University of Pittsburgh School of Medicine. Aaron Brown, M.D., assistant professor of emergency medicine, and Franziska Jovin, M.D., associate professor of medicine, will lead the study in the ED and hospital.
“Doctors prescribe antibiotics more often than they would like to because it can be really hard to tell if a patient has a lung infection or a non-infectious disease,” he said. “Also, viral infections look very much like bacterial infections, and X-rays typically cannot distinguish between the two. This study will examine whether a novel biomarker can help doctors make more informed decisions about using antibiotics.”
More than 1,500 lung infection patients will be needed to complete the Procalcitonin Antibiotic Consensus Trial (ProACT), which will eventually be expanded to include approximately 10 other sites across the country.
Patients diagnosed in the ED with a lung infection and who are not critically ill will be asked to join ProACT. If they agree, patients will be randomly assigned to either get usual care or to also have a blood test to measure the level of the protein procalcitonin, which previous Swiss studies have shown is high with bacterial infection and low with viral infection. The result and a recommendation about antibiotic use will be available within an hour to the treating ED physician. If the patient is admitted to the hospital, follow-up procalcitonin levels will be checked and made available to the treating hospital physician. The research team will call study patients twice within 30 days of the ED visit to check on their health status and the period of antibiotic use, if any.
“The final decision to use or not use antibiotics is up to the doctor, who also will be taking into account the patient’s medical history and other factors,” Dr. Huang said. “My hope is that we’ll find that patient outcomes are as just as good, while antibiotic use declines.”
ProACT is funded by a $5 million, five-year grant, and a one-year trial planning grant, from the National Institute of General Medical Sciences, part of the National Institutes of Health.
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018